| Literature DB >> 31975387 |
Jenna Rossoff1, Van Huynh2, Rachel E Rau3, Margaret E Macy4, Maria L Sulis5, Kirk R Schultz6, Michael J Burke7, Uma Athale8, Maureen M O'Brien9, John J Gregory10, Inge M van der Sluis11, Frank G Keller12, Christian M Zwaan11, Meinolf Suttorp13, Nobuko Hijiya1.
Abstract
Ponatinib has proven to be effective in adults with Philadelphia chromosome-positive leukaemias, but data in paediatrics are scarce. Among paediatric patients with chronic myeloid leukaemia (n = 9) or acute lymphoblastic leukaemia (n = 12) treated with varying doses of ponatinib in 13 centres, 71% showed a decrease in disease burden after a median of three months. Ponatinib was well tolerated, with grade 3 toxicities occurring in 29% of patients. Toxicities were similar to those reported in adults, with the exception of arterial thrombotic events, which were not observed. Ponatinib has a favourable safety profile in this paediatric cohort, but dose-finding studies are needed.Entities:
Keywords: Philadelphia chromosome; acute lymphoblastic leukaemia; chronic myeloid leukaemia; paediatrics; ponatinib
Mesh：
Substances：
Year: 2020 PMID： 31975387 DOI： 10.1111/bjh.16338
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998